HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Del Prato, S. Articles by Bonadonna, R. C. Search for Related Content PubMed PubMed Citation Articles by Del Prato, S. Articles by Bonadonna, R. C. Social Bookmarking                What's this?

Phasic Insulin Release and Metabolic Regulation in Type 2 Diabetes

¹ Department of Endocrinology and Metabolism, Section of Diabetes, University of Pisa, Pisa, Italy
² Department of Endocrinology and Metabolism, Section of Endocrinology and Metabolism, School of Medicine, University of Verona, Verona, Italy

Type 2 diabetes is a heterogeneous disorder due to prevalent insulin resistance associated with deficient insulin secretion or to a prevalent defect of insulin secretion associated with impaired insulin action. The definition is supported by the high frequency at which insulin resistance can be demonstrated in type 2 diabetic patients. Nonetheless, insulin resistance is not a sufficient mechanism to cause diabetes. Impaired ß-cell function is a necessary defect in all conditions of impaired glucose regulation; however, it manifests itself in a different manner in fasting and glucose-stimulated conditions. In the fasting state, the basal insulin secretory rate increases as a function of the progressive decline in insulin action. As such, the fasting plasma insulin concentration is often taken as a marker for insulin sensitivity. After glucose challenge, a specific alteration of acute insulin release is an early and progressive defect. The latter might represent an intrinsic defect, but its continuous decline is affected by glucotoxicity and lipotoxicity. To understand the impact of ß-cell dysfunction in type 2 diabetes on metabolic homeostasis, it is useful to consider the different phases of insulin secretion separately. Insulin secretion can be divided into basal (postabsorptive) and stimulated (postprandial) states. The former prevails during the interprandial phases and plays a major role during the overnight fast; the latter regulates glucose metabolism when carbohydrate is abundant and must be disposed of. Data in animals and humans support a crucial physiological role of first-phase insulin secretion in postprandial glucose homeostasis. This effect is primarily achieved in the liver, allowing prompt inhibition of endogenous glucose production and limiting the postprandial rise in plasma glucose level. In type 2 diabetes, loss of the early surge of insulin release is an early and quite common defect that may have a pathogenetic role in the development of postprandial hyperglycemia, possibly requiring specific therapeutic intervention.

CiteULike

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				S. Belmadani, D. I. Palen, R. A. Gonzalez-Villalobos, H. A. Boulares, and K. Matrougui Elevated Epidermal Growth Factor Receptor Phosphorylation Induces Resistance Artery Dysfunction in Diabetic db/db Mice Diabetes, June 1, 2008; 57(6): 1629 - 1637. [Abstract] [Full Text] [PDF]

				H. E. Silber, P. M. Jauslin, N. Frey, R. Gieschke, U. S. H. Simonsson, and M. O. Karlsson An Integrated Model for Glucose and Insulin Regulation in Healthy Volunteers and Type 2 Diabetic Patients Following Intravenous Glucose Provocations J. Clin. Pharmacol., September 1, 2007; 47(9): 1159 - 1171. [Abstract] [Full Text] [PDF]

				C. Robertson Physiologic insulin replacement in type 2 diabetes: optimizing postprandial glucose control. The Diabetes Educator, May 1, 2006; 32(3): 423 - 432. [Abstract] [Full Text] [PDF]

				E N Fazio, M Everest, R Colman, R Wang, and C L Pin Altered Glut-2 accumulation and {beta}-cell function in mice lacking the exocrine-specific transcription factor, Mist1 J. Endocrinol., December 1, 2005; 187(3): 407 - 418. [Abstract] [Full Text] [PDF]

				D. E Laaksonen, L. K Toppinen, K. S Juntunen, K. Autio, K.-H. Liukkonen, K. S Poutanen, L. Niskanen, and H. M Mykkanen Dietary carbohydrate modification enhances insulin secretion in persons with the metabolic syndrome Am. J. Clinical Nutrition, December 1, 2005; 82(6): 1218 - 1227. [Abstract] [Full Text] [PDF]

				M. A. Bethel and M. N. Feinglos Basal Insulin Therapy in Type 2 Diabetes J Am Board Fam Med, May 1, 2005; 18(3): 199 - 204. [Abstract] [Full Text] [PDF]